Navigation Links
Harwood Feffer LLP Announces Investigation of Questcor Pharmaceuticals, Inc.
Date:9/20/2012

NEW YORK, Sept. 20, 2012 /PRNewswire/ -- Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of Questcor Pharmaceuticals, Inc. ("Questcor" or the "Company") (NASDAQ: QCOR), concerning whether the board has breached its fiduciary duties to shareholders.

(Logo:  http://photos.prnewswire.com/prnh/20120215/MM54604LOGO)

Questcor derives substantially all of its revenue from the sale of Repository Corticotropin Injection, also known as HP Acthar Gel (Acthar).  On September 14, 2012, one of the largest private insurance providers in the United States, Aetna, issued a Clinical Policy Bulletin stating that based on review of medical studies, Acthar was "not medically necessary" for several conditions for which it has been prescribed, as a result, Aetna would cease coverage of Acthar for those conditions.  The directors of Questcor owes fiduciary obligation to the Company and its shareholders in the management of the Company's assets.

Questcor shares have fallen over 48% since September 7, 2012, when Company stock closed as high as $51.97 per share.  Questcor is currently trading at $27.33 per share.

Current holders of Questcor shares purchased at any time may have a claim against the board for breaches of fiduciary duties, gross mismanagement, and/or abuse of control.  If you own Questcor shares and wish to discuss this matter with us, or have any questions concerning your rights and interests with regard to this matter, please contact:

Robert I. Harwood, Esq.
Matthew M. Houston, Esq.
Christopher J. Safrath
Harwood Feffer LLP
488 Madison Avenue
New York, New York 10022
Phone Numbers: (877) 935-7400
(212)935-7400
Email:        csafrath@hfesq.com
Website:    http://www.hfesq.com

Harwood Feffer has been representing individual and institutional investors for many years, serving as lead counsel in numerous cases in federal and state courts. Please visit the Harwood Feffer LLP website (http://www.hfesq.com) for more information about the firm.

Attorney Advertising. © 2012 Harwood Feffer LLP. The law firm responsible for this advertisement is Harwood Feffer LLP (www.hfesq.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter.


'/>"/>
SOURCE Harwood Feffer LLP
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cyberonics Announces Investment In cerbomed GmbH
2. ULURU Inc. Announces First Order Of Altrazeal For European Launch
3. United Therapeutics Announces Collaboration With Ascendis Pharma To Develop Self-Injectable Treprostinil For Pulmonary Arterial Hypertension
4. FDAnews announces Third Annual Pharmaceutical Labeling Summit
5. CVS Caremark Corporation Announces New Share Repurchase Authorization for up to $6 Billion of Common Stock
6. PRN Physician Recommended Nutriceuticals announces partnership with Dr. Eric Donnenfeld and expansion in the New York City metropolitan area
7. InnoPharma, Inc., Announces U.S. FDA Approval of Acetylcysteine Solution, USP, 20% for Inhalation or Oral Administration
8. Specialty Pharmacy Certification Board Announces Inaugural Board of Directors
9. Valeant Pharmaceuticals Announces Launch of Concurrent Private Offerings of Senior Notes
10. Golden Meditech Holdings Limited Announces Updates on Medical Devices Subsidiary Latest Development
11. Active Life Announces Launch of Next Generation BioDentTM for Life Science Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2019)... ... September 18, 2019 , ... NDA Partners Chairman ... well-respected preclinical drug development expert with a focus in the cardiovascular and metabolic ... to joining NDA Partners, Dr. Hoffmann served as Executive Director of Preclinical Safety ...
(Date:9/17/2019)... New Zealand (PRWEB) , ... September 17, 2019 , ... ... in in Fast Company’s 2019 Innovation by Design Awards Students category. , It was ... at the Auckland Bioengineering Institute. , Muss-Bits is comprised of two parts. A “sensor ...
(Date:9/17/2019)... ... 2019 , ... Scientists writing in a 2017 issue of ... progressive destruction of joint cartilage in osteoarthritis are “on the close horizon.” ... orthopedic surgeon Alejandro Badia, MD , founder and chief medical officer of ...
Breaking Medicine Technology:
(Date:9/17/2019)... ... 17, 2019 , ... Caravan Health is seeking ... the country, the company announced today. High-performing community health systems and providers can ... cost efficiency. This opportunity is open to those new to value-based Medicare payment ...
(Date:9/17/2019)... PASO ROBLES, Calif. (PRWEB) , ... September 17, ... ... Pismo Beach , CA, recently announced that he has been certified by the ... Botox in dentistry is used to correct a wide range of orofacial conditions ...
(Date:9/17/2019)... BOSTON (PRWEB) , ... September 17, 2019 , ... ... Participation (CISCRP) is pleased to announce the release of the third edition of ... a comprehensive, easy-to-read guide for patients, caregivers and families to navigate the clinical ...
(Date:9/14/2019)... ... September 13, 2019 , ... ... detection and treatment of infectious diseases at its annual Congress (WMIC) recently ... detection of residual HIV infected cell persistence and the development of pathogen-specific ...
(Date:9/11/2019)... ... September 12, 2019 , ... “Heart Seizures”: a useful ... coronary artery disease as he hopes to prevent anyone from having it and to ... author John Saltwick, a writer who was diagnosed with coronary artery disease. Predicted to ...
Breaking Medicine News(10 mins):